Posaconazole Tablets Suppliers & Bulk Manufacturers
Available Forms: Delayed-Release Tablets
Available Strengths: 300 mg
Reference Brands: Noxafil(US & EU)
Category:
Anti-fungal
Posaconazole delayed-release tablets inhibit fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis essential for fungal cell membranes. They provide broad-spectrum antifungal activity, improved absorption, and enhanced bioavailability. Benefits include effective prophylaxis and treatment of invasive fungal infections, with convenient dosing, making them vital for managing severe fungal diseases.
Posaconazole Tablets is available in Delayed-Release Tablets
and strengths such as 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Posaconazole Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Posaconazole Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Posaconazole delayed-release tablets are approved in the EU and US for prophylaxis and treatment of invasive fungal infections. In the EU, MSD’s Noxafil is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on comprehensive clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and continuous safety monitoring. For expert assistance with dossiers, regulatory submissions, and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory solutions. We facilitate efficient market access for posaconazole delayed-release tablets, ensuring adherence to European and American standards for safe, effective antifungal therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing